For many people using GLP-1 medications for weight management, one of the biggest questions comes after the weight is lost: do you really need to continue taking the medication every single week forever?

A 2026 peer-reviewed study from Scripps Clinic researchers offers an intriguing early answer. In a small case series, adults who had already reached a weight-loss plateau on weekly semaglutide or tirzepatide transitioned to less-frequent maintenance dosing. The group maintained its previous improvements and, on average, lost a little additional weight during the reduced-frequency period.

The Scripps GLP-1 maintenance study

The study, Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series, was authored by Michelle Wong, Ash Wu, Pawanjot K. Garhe and Mitch Biermann and published in Obesity in 2026.

Study: Wong M, Wu A, Garhe PK, Biermann M. Obesity. 2026;34(Suppl 1):112–120. DOI: 10.1002/oby.70137. View the study on PubMed or read the full open-access article.

What did researchers do?

This was a retrospective case series of 30 adults who had achieved a weight plateau while taking weekly semaglutide or tirzepatide. Participants then transitioned to reduced-frequency dosing, usually every other week, at their existing dose.

That distinction matters: this was primarily a study of extending the interval between doses, not simply giving everyone tiny “microdoses.”

What happened to their weight?

The average body weight changed from 87.9 kg (about 194 lb) before treatment to 74.1 kg (about 163 lb) at the weekly-treatment plateau, then to 72.4 kg (about 160 lb) during reduced-frequency maintenance.

So the group did not regain its lost weight after reducing treatment frequency. Average weight actually declined another 1.7 kg, or about 3.7 pounds. Participants maintained reduced-frequency dosing for an average of 36.3 weeks.

What about body composition?

The researchers also evaluated body composition. Total body fat and truncal fat continued to decline while skeletal muscle mass stabilized during reduced-frequency therapy. Metabolic improvements achieved during weekly treatment were also maintained.

Does this mean a GLP-1 can be taken every 2–6 weeks?

Not as a general rule. The study provides early evidence that reduced-frequency maintenance may work for selected patients who have already responded successfully to treatment, but it does not establish an every-two-week or every-six-week regimen for everyone.

Some patients in the case series reported progressively extending their intervals, including much longer intervals in certain cases. That is very different from proving that a six-week schedule is broadly effective or appropriate.

The limitations matter

This was a small, retrospective case series, not a randomized controlled trial. Participants had already responded to GLP-1 therapy and reached a relatively stable weight before trying reduced-frequency treatment. The results therefore should not be interpreted as evidence that anyone taking semaglutide or tirzepatide can simply begin spacing doses farther apart and expect the same outcome.

The authors describe reduced-frequency maintenance as a promising strategy worthy of further study and call for larger controlled research.

Reduced-frequency dosing vs. GLP-1 “microdosing”

These ideas are often lumped together online, but they are not the same thing. “Microdosing” generally refers to using an amount below a standard therapeutic dose. Reduced-frequency dosing, as studied here, means increasing the time between injections after successful treatment while generally maintaining the established dose.

Why this research matters

Long-term maintenance is becoming one of the biggest questions in GLP-1 treatment. If larger trials confirm these findings, individualized reduced-frequency maintenance could potentially decrease injection burden and treatment costs while helping some patients preserve their results.

The most interesting possibility raised by this research is that the treatment schedule needed to maintain weight loss may not always have to be identical to the schedule needed to achieve it.

The bottom line

The viral version of this story — “you can take your GLP-1 once every six weeks” — goes further than the evidence supports. What the Scripps study actually found is still compelling: 30 adults who had already achieved substantial weight loss on weekly semaglutide or tirzepatide transitioned to reduced-frequency maintenance, usually every other week, and as a group maintained their weight, body-composition and metabolic improvements over an average of about nine months.

It’s early evidence, not a new dosing guideline. But it raises an important research question: could long-term GLP-1 maintenance eventually be individualized around the lowest treatment frequency that preserves a person’s results?

Study reference

Wong M, Wu A, Garhe PK, Biermann M. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity. 2026;34(Suppl 1):112–120. DOI: 10.1002/oby.70137.

Medical disclaimer: This article is for educational and informational purposes only and is not medical advice. Patients should discuss changes to prescribed semaglutide, tirzepatide or other medication schedules with a qualified healthcare professional.